8-K: Teva Pharmaceuticals Reports Strong Q2 2026 Results, Raises Outlook

Teva Pharmaceutical Industries Ltd. announced robust second-quarter 2026 financial results, driven by significant growth in its key innovative brands, leading to an upward revision of its full-year outlook.

Summary

• Teva Pharmaceutical Industries Ltd. reported Q2 2026 revenues of $4.1 billion, a 1% decrease year-over-year in USD and 3% in local currency, primarily due to lower generics revenue.
• Key innovative brands (AUSTEDO, AJOVY, UZEDY) collectively grew 43% year-over-year in local currency, exceeding $1 billion in revenue.
• The company raised its 2026 revenue outlook for these three key innovative brands to approximately $3.7 billion, representing about 17% year-over-year growth.
• Generics revenue decreased by 15% year-over-year in local currency, largely attributed to lower sales of lenalidomide capsules in the U.S. due to increased competition.
• Teva acquired Emalex Biosciences for approximately $700 million to bolster its neuroscience pipeline with ecopipam, a therapy for Tourette syndrome.
• The company is transitioning its American Depositary Share (ADS) program to a direct listing of ordinary shares on the NYSE, effective September 14, 2026.
• Q2 2026 GAAP loss per share was $0.49, impacted by $726 million in expenses related to the Emalex acquisition.
• Non-GAAP diluted EPS for Q2 2026 was $0.02, also reflecting the Emalex acquisition's impact.
• Cash flow from operating activities was $411 million, and free cash flow was $622 million in Q2 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong execution on the 'Pivot to Growth' strategy driving innovative brand performance and leading to an improved outlook, despite expected headwinds in the generics segment.

Positives

• Key innovative brands (AUSTEDO, AJOVY, UZEDY) demonstrated strong growth, collectively increasing revenue by 43% year-over-year in local currency to over $1 billion.
• The company raised its 2026 revenue outlook for AUSTEDO, AJOVY, and UZEDY to approximately $3.7 billion.
• AUSTEDO global revenues reached $696 million, up 40% YoY in LC.
• AJOVY global revenues increased to $244 million, up 56% YoY in LC.
• UZEDY revenues grew to $77 million, up 43% YoY in LC, positioning it as a strong contender in the atypical LAI market for schizophrenia.
• Biosimilars portfolio is on track to deliver $800 million in revenues by 2027.
• Acquisition of Emalex Biosciences strengthens the innovative neuroscience pipeline with ecopipam.
• Fitch Ratings upgraded Teva's corporate credit rating to Investment Grade BBB-.
• Free cash flow increased to $622 million in Q2 2026 from $476 million in Q2 2025.
• Gross profit margin improved to 52.0% from 50.3% year-over-year.

Negatives

• Overall Q2 2026 revenues decreased by 1% in USD and 3% in local currency compared to Q2 2025, primarily due to lower generics revenues.
• Global generics revenues decreased by 15% year-over-year in local currency, significantly impacted by lower sales of lenalidomide capsules in the U.S.
• Reported a GAAP loss per share of $0.49 for Q2 2026, largely due to $726 million in acquisition-related expenses for Emalex.
• Non-GAAP operating income decreased to $375 million from $1,133 million year-over-year.
• Adjusted EBITDA decreased by 62% to $474 million compared to $1,233 million in Q2 2025.
• United States segment profit turned into a loss of $76 million from a profit of $699 million year-over-year, primarily due to increased R&D expenses from the Emalex acquisition.
• The U.S. segment's generic products revenue decreased by 31%.

Risks

• Continued competition in the generics market, particularly impacting lenalidomide capsules in the U.S.
• Potential delays in the launch of new generic products.
• Challenges in developing and commercializing additional pharmaceutical products in a timely manner.
• Intense competition for innovative medicines.
• Risks associated with integrating the Emalex Biosciences acquisition and achieving expected results from ecopipam.
• Potential for significant disruptions to information technology systems, including cybersecurity attacks.
• Interruption in the supply chain or problems with internal or third-party manufacturing.
• Compliance with complex legal and regulatory requirements and potential for increased regulatory oversight.

Future Outlook

Teva raised its 2026 revenue outlook for its three key innovative brands (AUSTEDO, AJOVY, UZEDY) to approximately $3.7 billion, reflecting an estimated 17% year-over-year growth. The overall 2026 revenue outlook is projected to be between $16.5 billion and $16.85 billion. Non-GAAP operating income is expected to be between $3.8 billion and $4.0 billion, and Adjusted EBITDA between $4.23 billion and $4.53 billion. Non-GAAP diluted EPS is projected to be between $1.91 and $2.11, and free cash flow between $2.0 billion and $2.4 billion.

Management Comments

• "Our second quarter reflects continued execution of our Pivot to Growth strategy. During the quarter, and into July, we advanced several value-creating assets, including two additional indications for duvakitug, demonstrating its pipeline-in-a-product potential, the acquisition and NDA submission of ecopipam (EBS-101), continued progress for olanzapine LAI, and expansion of our biosimilars pipeline through strategic collaborations."
• "Our key Innovative brands collectively generated over $1 billion in revenues, continuing to transform Teva's portfolio mix and financial profile. The breadth of these milestones underscores the increasingly diversified nature of Teva's growth profile. We are strengthening our neuroscience and immunology pipeline, expanding access through biosimilars, and continuing to modernize the business to support sustainable, innovation-driven growth and long-term value creation for patients and shareholders."

Industry Context

StockSavvy.ai notes that Teva's Q2 2026 results highlight a strategic shift towards higher-margin innovative products, a trend seen across the pharmaceutical industry as companies seek to offset patent expirations and generic competition. The strong performance of AUSTEDO, AJOVY, and UZEDY, coupled with the acquisition of ecopipam, aligns with this industry-wide focus on specialized and innovative therapies, particularly in neuroscience and immunology.

Comparison to Industry Standards

• Teva's innovative brands' collective growth of 43% YoY in local currency significantly outpaces the typical growth rates for established blockbuster drugs in mature markets, indicating strong market penetration and demand.
• The acquisition of Emalex Biosciences for $700 million for a single asset (ecopipam) reflects the high valuations and strategic importance placed on novel therapies in the neuroscience sector, a trend observed across major pharmaceutical players like Pfizer, Merck, and AbbVie when acquiring early-to-mid-stage pipeline assets.
• The company's stated goal of achieving a 30% non-GAAP operating income margin by 2027 is ambitious but aligns with the profitability targets of leading biopharmaceutical companies that have successfully transitioned their portfolios towards innovative medicines.
• The upgrade by Fitch Ratings to Investment Grade BBBis a positive signal, reflecting improved financial health and strategic execution, which is a benchmark for financial stability sought by institutional investors in the pharmaceutical sector.

Legal Proceedings

• Ongoing antitrust litigations in the U.S.
• Opioid cases settlement provisions.
• Claims brought by attorneys general in generic drug antitrust litigation.

Stakeholder Impact

• Shareholders: Potential for increased value driven by the growth of innovative brands and improved financial outlook; transition to direct listing may broaden shareholder base and improve index inclusion.
• Patients: Continued access to innovative treatments (AUSTEDO, AJOVY, UZEDY) and development of new therapies (ecopipam, olanzapine LAI, TEV-408, duvakitug).
• Employees: Impacted by ongoing transformation programs, which may include restructuring, but also potential for growth in innovative areas.
• Creditors: Improved financial standing indicated by Fitch's upgrade to Investment Grade BBB-.

Next Steps

• Commencement of trading of ordinary shares on the NYSE on September 14, 2026.
• Initiation of Phase 2 study for TEV-408 (anti-IL-15) in vitiligo expected in Q4 2026.
• Launch of olanzapine LAI in the U.S. is on track for Q4 2026, subject to regulatory approval.
• Continued execution of Teva Transformation programs to achieve targeted savings and a 30% non-GAAP operating income margin by 2027.
• Divestiture of the API business is being pursued, though timing and completion are uncertain.

Key Dates

Recommendation

While the growth in innovative brands and raised outlook are positive, the overall revenue decline, significant GAAP loss, and continued challenges in the generics segment warrant a cautious approach. The strategic shift is promising, but the full impact of the Emalex acquisition and the transition to a direct listing need to be monitored. A 'hold' recommendation reflects the balance of positive strategic execution against ongoing financial pressures and market dynamics.

Keywords

pharmaceuticals, generics, innovative brands, AUSTEDO, AJOVY, UZEDY, biosimilars, neuroscience pipeline